|
1
|
Capper D, Jones DTW, Sill M, Hovestadt V,
Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, et al:
DNA methylation-based classification of central nervous system
tumours. Nature. 555:469–474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mandel JJ, Yust-Katz S, Patel AJ, Cachia
D, Liu D, Park M, Yuan Y, Kent TA and de Groot JF: Inability of
positive phase II clinical trials of investigational treatments to
subsequently predict positive phase III clinical trials in
glioblastoma. Neuro Oncol. 20:113–122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ronellenfitsch MW, Steinbach JP and Wick
W: Epidermal growth factor receptor and mammalian target of
rapamycin as therapeutic targets in malignant glioma: Current
clinical status and perspectives. Target Oncol. 5:183–191. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van Den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. New Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bowman RL, Klemm F, Akkari L, Pyonteck SM,
Sevenich L, Quail DF, Dhara S, Simpson K, Gardner EE,
Iacobuzio-Donahue CA, et al: Macrophage ontogeny underlies
differences in tumor-specific education in brain malignancies. Cell
Rep. 17:2445–2459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klemm F, Maas RR, Bowman RL, Kornete M,
Soukup K, Nassiri S, Brouland JP, Iacobuzio-Donahue CA, Brennan C,
Tabar V, et al: Interrogation of the microenvironmental landscape
in brain tumors reveals disease-specific alterations of immune
cells. Cell. 181:1643–1660. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friebel E, Kapolou K, Unger S, Núñez NG,
Utz S, Rushing EJ, Regli L, Weller M, Greter M, Tugues S, et al:
Single-cell mapping of human brain cancer reveals tumor-specific
instruction of tissue-invading leukocytes. Cell. 181:1626–1642.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gabrusiewicz K, Rodriguez B, Wei J,
Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad
A, et al: Glioblastoma-infiltrated innate immune cells resemble M0
macrophage phenotype. JCI Insight. 1:e858412016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Selenica MLB, Alvarez JA, Nash KR, Lee DC,
Cao C, Lin X, Reid P, Mouton PR, Morgan D and Gordon M: Diverse
activation of microglia by chemokine (C-C motif) ligand 2
overexpression in brain. J Neuroinflammation. 10:8562013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stables MJ, Shah S, Camon EB, Lovering RC,
Newson J, Bystrom J, Farrow S and Gilroy DW: Transcriptomic
analyses of murine resolution-phase macrophages. Blood.
118:e192–e208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Szulzewsky F, Pelz A, Feng X, Synowitz M,
Markovic D, Langmann T, Holtman IR, Wang X, Eggen BJ, Boddeke HW,
et al: Glioma-associated microglia/macrophages display an
expression profile different from M1 and M2 polarization and highly
express Gpnmb and Spp1. PLoS One. 10:e01166442015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeiner PS, Preusse C, Blank AE, Zachskorn
C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke
H, Reiß S, et al: MIF receptor CD74 is restricted to
microglia/macrophages, associated with a M1-polarized immune milieu
and prolonged patient survival in gliomas. Brain Pathol.
25:491–504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Keane L, Cheray M, Blomgren K and Joseph
B: Multifaceted microglia-key players in primary brain tumour
heterogeneity. Nat Rev Neurol. 17:243–259. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gieryng A, Pszczolkowska D, Walentynowicz
KA, Rajan WD and Kaminska B: Immune microenvironment of gliomas.
Lab Invest. 97:498–518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kennedy BC, Showers CR, Anderson DE,
Anderson L, Canoll P, Bruce JN and Anderson RCE: Tumor-associated
macrophages in glioma: Friend or foe? J Oncol. 2013:4869122013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeiner PS, Preusse C, Golebiewska A, Zinke
J, Iriondo A, Muller A, Kaoma T, Filipski K, Müller-Eschner M,
Bernatz S, et al: Distribution and prognostic impact of
microglia/macrophage subpopulations in gliomas. Brain Pathol.
29:513–529. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaffes I, Szulzewsky F, Chen Z, Herting
CJ, Gabanic B, Vega JE, Shelton J, Switchenko JM, Ross JL, McSwain
LF, et al: Human mesenchymal glioblastomas are characterized by an
increased immune cell presence compared to proneural and classical
tumors. Oncoimmunology. 8:e16553602019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klemm F, Möckl A, Salamero-Boix A,
Alekseeva T, Schäffer A, Schulz M, Niesel K, Maas RR, Groth M, Elie
BT, et al: Compensatory CSF2-driven macrophage activation promotes
adaptive resistance to CSF1R inhibition in breast-to-brain
metastasis. Nat Cancer. 2:1086–1101. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niesel K, Schulz M, Anthes J, Alekseeva T,
Macas J, Salamero-Boix A, Möckl A, Oberwahrenbrock T, Lolies M,
Stein S, et al: The immune suppressive microenvironment affects
efficacy of radio-immunotherapy in brain metastasis. EMBO Mol Med.
13:e134122021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ronellenfitsch MW, Brucker DP, Burger MC,
Wolking S, Tritschler F, Rieger J, Wick W, Weller M and Steinbach
JP: Antagonism of the mammalian target of rapamycin selectively
mediates metabolic effects of epidermal growth factor receptor
inhibition and protects human malignant glioma cells from
hypoxia-induced cell death. Brain. 132:1509–1522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thiepold AL, Lorenz NI, Foltyn M, Engel
AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, et al:
Mammalian target of rapamycin complex 1 activation sensitizes human
glioma cells to hypoxia-induced cell death. Brain. 140:2623–2638.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu GY and Sabatini DM: mTOR at the nexus
of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol.
21:183–203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
García-Martínez JM and Alessi DR: mTOR
complex 2 (mTORC2) controls hydrophobic motif phosphorylation and
activation of serum- and glucocorticoid-induced protein kinase 1
(SGK1). Biochem J. 416:375–385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heinzen D, Divé I, Lorenz NI, Luger AL,
Steinbach JP and Ronellenfitsch MW: Second generation mTOR
inhibitors as a double-edged sword in malignant glioma treatment.
Int J Mol Sci. 20:44742019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ronellenfitsch MW, Zeiner PS, Mittelbronn
M, Urban H, Pietsch T, Reuter D, Senft C, Steinbach JP, Westphal M
and Harter PN: Akt and mTORC1 signaling as predictive biomarkers
for the EGFR antibody nimotuzumab in glioblastoma. Acta Neuropathol
Commun. 6:812018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chinnaiyan P, Won M, Wen PY, Rojiani AM,
Werner-Wasik M, Shih HA, Ashby LS, Yu HH, Stieber VW, Malone SC, et
al: A randomized phase II study of everolimus in combination with
chemoradiation in newly diagnosed glioblastoma: Results of NRG
oncology RTOG 0913. Neuro Oncol. 20:666–673. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wick W, Dettmer S, Berberich A, Kessler T,
Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B,
Debus J, et al: N2M2 (NOA-20) phase I/II trial of molecularly
matched targeted therapies plus radiotherapy in patients with newly
diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol.
21:95–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alexander BM, Ba S, Berger MS, Berry DA,
Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, et
al: Adaptive global innovative learning environment for
glioblastoma: GBM AGILE. Clin Cancer Res. 24:737–743. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Divé I, Klann K, Michaelis JB, Heinzen D,
Steinbach JP, Münch C and Ronellenfitsch MW: Inhibition of mTOR
signaling protects human glioma cells from hypoxia-induced cell
death in an autophagy-independent manner. Cell Death Discov.
8:4092022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sauer B, Lorenz NI, Divé I, Klann K, Luger
AL, Urban H, Schröder JH, Steinbach JP, Münch C and Ronellenfitsch
MW: Mammalian target of rapamycin inhibition protects glioma cells
from temozolomide-induced cell death. Cell Death Discov. 10:82024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wick W, Gorlia T, Bady P, Platten M, van
den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A,
et al: Phase II study of radiotherapy and temsirolimus versus
radiochemotherapy with temozolomide in patients with newly
diagnosed glioblastoma without MGMT promoter hypermethylation
(EORTC 26082). Clin Cancer Res. 22:4797–4806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Harter PN, Jennewein L, Baumgarten P,
Ilina E, Burger MC, Thiepold AL, Tichy J, Zörnig M, Senft C,
Steinbach JP, et al: Immunohistochemical assessment of
phosphorylated mTORC1-pathway proteins in human brain tumors. PLoS
One. 10:e01271232015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weichhart T, Hengstschläger M and Linke M:
Regulation of innate immune cell function by mTOR. Nat Rev Immunol.
15:599–614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Weichhart T, Costantino G, Poglitsch M,
Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH,
Hengstschläger M, et al: The TSC-mTOR signaling pathway regulates
the innate inflammatory response. Immunity. 29:565–577. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soave DF, Miguel MP, Tomé FD, de Menezes
LB, Nagib PRA and Celes MRN: The fate of the tumor in the hands of
microenvironment: Role of TAMs and mTOR pathway. Mediators Inflamm.
2016:89105202016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li D, Wang C, Yao Y, Chen L, Liu G, Zhang
R, Liu Q, Shi FD and Hao J: mTORC1 pathway disruption ameliorates
brain inflammation following stroke via a shift in microglia
phenotype from M1 type to M2 type. FASEB J. 30:3388–3399. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xie L, Sun F, Wang J, Mao X, Xie L, Yang
SH, Su DM, Simpkins JW, Greenberg DA and Jin K: mTOR signaling
inhibition modulates macrophage/microglia-mediated
neuroinflammation and secondary injury via regulatory T cells after
focal ischemia. J Immunol. 192:6009–6019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Keane L, Antignano I, Riechers SP,
Zollinger R, Dumas AA, Offermann N, Bernis ME, Russ J, Graelmann F,
McCormick PN, et al: mTOR-dependent translation amplifies microglia
priming in aging mice. J Clin Invest. 131:e1327272021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu Y, Mai W, Chen L, Cao K, Zhang B, Zhang
Z, Liu Y, Lou H, Duan S and Gao Z: mTOR-mediated metabolic
reprogramming shapes distinct microglia functions in response to
lipopolysaccharide and ATP. Glia. 68:1031–1045. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lisi L, Laudati E, Navarra P and dello
Russo C: The mTOR kinase inhibitors polarize glioma-activated
microglia to express a M1 phenotype. J Neuroinflammation.
11:1252014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lisi L, Ciotti GMP, Chiavari M,
Pizzoferrato M, Mangiola A, Kalinin S, Feinstein DL and Navarra P:
Phospho-mTOR expression in human glioblastoma microglia-macrophage
cells. Neurochem Int. 129:1044852019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dumas AA, Pomella N, Rosser G, Guglielmi
L, Vinel C, Millner TO, Rees J, Aley N, Sheer D, Wei J, et al:
Microglia promote glioblastoma via mTOR-mediated immunosuppression
of the tumour microenvironment. EMBO J. 39:e1037902020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Garcia-Mesa Y, Jay TR, Checkley MA, Luttge
B, Dobrowolski C, Valadkhan S, Landreth GE, Karn J and
Alvarez-Carbonell D: Immortalization of primary microglia: A new
platform to study HIV regulation in the central nervous system. J
Neurovirol. 23:47–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Janabi N, Peudenier S, Héron B, Ng KH and
Tardieu M: Establishment of human microglial cell lines after
transfection of primary cultures of embryonic microglial cells with
the SV40 large T antigen. Neurosci Lett. 195:105–108. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dello Russo C, Cappoli N, Coletta I,
Mezzogori D, Paciello F, Pozzoli G, Navarra P and Battaglia A: The
human microglial HMC3 cell line: Where do we stand? A systematic
literature review. J Neuroinflammation. 15:2592018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Studer A, de Tribolet N, Diserens AC,
Gaide AC, Matthieu JM, Carrel S and Stavrou D: Characterization of
four human malignant glioma cell lines. Acta Neuropathol.
66:208–217. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wischhusen J, Naumann U, Ohgaki H,
Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent,
induces p53-dependent and p53-independent glioma cell death.
Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lorenz NI, Sittig ACM, Urban H, Luger AL,
Engel AL, Münch C, Steinbach JP and Ronellenfitsch MW: Activating
transcription factor 4 mediates adaptation of human glioblastoma
cells to hypoxia and temozolomide. Sci Rep. 11:141612021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Roth W, Fontana A, Trepel M, Reed JC,
Dichgans J and Weller M: Immunochemotherapy of malignant glioma:
Synergistic activity of CD95 ligand and chemotherapeutics. Cancer
Immunol Immunother. 44:55–63. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Steinbach JP, Wolburg H, Klumpp A, Probst
H and Weller M: Hypoxia-induced cell death in human malignant
glioma cells: Energy deprivation promotes decoupling of
mitochondrial cytochrome c release from caspase processing and
necrotic cell death. Cell Death Differ. 10:823–832. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schulz M, Michels B, Niesel K, Stein S,
Farin H, Rödel F and Sevenich L: Cellular and molecular changes of
brain metastases-associated myeloid cells during disease
progression and therapeutic response. iScience. 23:1011782020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Michels BE, Mosa MH, Grebbin BM, Yepes D,
Darvishi T, Hausmann J, Urlaub H, Zeuzem S, Kvasnicka HM, Oellerich
T and Farin HF: Human colon organoids reveal distinct physiologic
and oncogenic Wnt responses. J Exp Med. 216:704–720. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim D, Pertea G, Trapnell C, Pimentel H,
Kelley R and Salzberg SL: TopHat2: Accurate alignment of
transcriptomes in the presence of insertions, deletions and gene
fusions. Genome Biol. 14:R362013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Westphal M, Heese O, Steinbach JP, Schnell
O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C,
et al: A randomised, open label phase III trial with nimotuzumab,
an anti-epidermal growth factor receptor monoclonal antibody in the
treatment of newly diagnosed adult glioblastoma. Eur J Cancer.
51:522–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
He S, Kato K, Jiang J, Wahl DR, Mineishi
S, Fisher EM, Murasko DM, Glick GD and Zhang Y: Characterization of
the metabolic phenotype of rapamycin-treated CD8+ T cells with
augmented ability to generate long-lasting memory cells. PLoS One.
6:e201072011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mills CD, Kincaid K, Alt JM, Heilman MJ
and Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J
Immunol. 164:6166–6173. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Platten M, Bunse L, Wick A, Bunse T, Le
Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, et al: A
vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature.
592:463–468. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Burger MC, Forster MT, Romanski A,
Straßheimer F, Macas J, Zeiner PS, Steidl E, Herkt S, Weber KJ,
Schupp J, et al: Intracranial injection of NK cells engineered with
a HER2-targeted chimeric antigen receptor in patients with
recurrent glioblastoma. Neuro Oncol. 25:2058–2071. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Omuro A, Brandes AA, Carpentier AF, Idbaih
A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M,
Bähr O, et al: Radiotherapy combined with nivolumab or temozolomide
for newly diagnosed glioblastoma with unmethylated MGMT promoter:
An international randomized phase III trial. Neuro Oncol.
25:123–134. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lim M, Weller M, Idbaih A, Steinbach J,
Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat
J, et al: Phase III trial of chemoradiotherapy with temozolomide
plus nivolumab or placebo for newly diagnosed glioblastoma with
methylated MGMT promoter. Neuro Oncol. 24:1935–1949. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gunasegaran B, Krishnamurthy S, Chow SS,
Villanueva MD, Guller A, Ahn SB and Heng B: Comparative analysis of
HMC3 and C20 microglial cell lines reveals differential myeloid
characteristics and responses to immune stimuli. Immunology.
175:84–102. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur
W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, et al:
Characterization of Torin2, an ATP-competitive inhibitor of mTOR,
ATM, and ATR. Cancer Res. 73:2574–2586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wick W, Lanz LM, Wick A, Harting I,
Dettmer S, Suwala AK, Ketter R, Tabatabai G, Seliger-Behme C, Glas
M, et al: N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly
matched targeted therapies plus radiotherapy in patients with newly
diagnosed glioblastoma without MGMT promoter hypermethylation. J
Clin Oncol. 42:20002024. View Article : Google Scholar
|
|
66
|
Strecker MI, Wlotzka K, Strassheimer F,
Roller B, Ludmirski G, König S, Röder J, Opitz C, Alekseeva T, Reul
J, et al: AAV-mediated gene transfer of a checkpoint inhibitor in
combination with HER2-targeted CAR-NK cells as experimental therapy
for glioblastoma. Oncoimmunology. 11:21275082022. View Article : Google Scholar : PubMed/NCBI
|
